GROUP CLASS ACTION: AN EMERGING LEGAL RISK FOR PHARMA BUSINESSES

Michael Frisby of Stevens & Bolton warns pharma companies that they may soon find themselves the target of a group action given the regulatory attention focused on the pharma sector and the appetite amongst litigation funders to invest in group actions, and cites recent examples where claims alleging breaches of competition law or high profile consumer claims were brought. Read more.

Keep Reading

Insights

A WAVE OF DISPUTES ON THE HORIZON FOR PHARMA

Michael Frisby and Robert Eriksson of Stevens & Bolton predict that, with the record fines being imposed in the pharmaceutical industry for competition law breaches, life science companies could soon become targets of claimant law firms and litigation funders pursuing group claims.

Before You Go

Never miss a thing in the litigation finance market.